ERBB2 and neoplasm: As previously reported, multiplex sequencing of tumour samples from patients with gastroesophageal cancer is feasible and does identify potentially actionable targets, in most cases amplification of known oncogenes such as ERBB2, EGFR, FGFR1–3, KRAS and MET, in a significant proportion of patients.